Research programme: cancer therapeutics - Collaborations Pharmaceuticals
Latest Information Update: 20 Mar 2023
Price :
$50 *
At a glance
- Originator Collaborations Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Chordoma; Neuroblastoma
Most Recent Events
- 20 Mar 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route), before March 2023 (Collaborations Pharmaceuticals pipeline, March 2022)
- 20 Mar 2023 Preclinical trials in Chordoma in USA (unspecified route), before March 2023 (Collaborations Pharmaceuticals pipeline, March 2022)
- 20 Mar 2023 Research programme: cancer therapeutics - Collaborations Pharmaceuticals receives Orphan Drug status for Chordoma in USA